https://kstockbriefing.com
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced the additional listing of 57,364 new common shares on November 13, 2024, issued following the exercise of stock options. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Total Issued Shares and Stock Quantity Changes Post-Listing This…
![[Disclosure] ALTEOGEN (196170) – Decision on Merger / 2024-11-07](https://kstockbriefing.com/wp-content/uploads/2026/08/포맷변환알테오젠.jpg)
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Alteogen announced that its major subsidiary, Altos Biologics, will absorb and merge with affiliated company Alteogen Healthcare (Merger Date: December 24, 2024) to integrate organizational structures and enhance management efficiency. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Tracking Completion…
Read More “[Disclosure] ALTEOGEN (196170) – Decision on Merger / 2024-11-07” »
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Due to an intra-group subsidiary merger (Altos Biologics absorbing Alteogen Healthcare), Alteogen will acquire 859,018 new shares (approx. KRW 31.17B) of Altos Biologics, increasing its stake to 63.46% with no additional cash outlay. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint)…
![[Disclosure] Samsung Biologics (207940) – (Correction) Major Management Matters Related to Investment Decisions / 2024-10-29](https://kstockbriefing.com/wp-content/uploads/2026/07/포맷변환-삼성바이오로직스.jpg)
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a correction disclosure regarding its Letter of Intent (LOI) for a biopharmaceutical contract manufacturing agreement with a Europe-based pharmaceutical company, extending the contract period and disclosure postponement deadline for the counterparty’s identity from October 31, 2024, to December 31, 2024, upon the…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a correction disclosure regarding its Letter of Intent (LOI) for a biopharmaceutical contract manufacturing agreement with a Europe-based pharmaceutical company, extending the contract period and disclosure postponement deadline for the counterparty’s identity from October 31, 2024, to December 31, 2024, upon the…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced that it plans to disclose its provisional financial results for the period from January 1, 2024, to September 30, 2024, on November 8, 2024. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring the Official Disclosure Submission and…
Read More “[Disclosure] Celltrion (068270) – Advance Notice of Earnings Release / 2024-10-29” »
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced its decision to acquire 537,924 common shares, valued at approximately KRW 100.0B, through direct open-market purchases. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Tracking the Completion of Treasury Share Purchases and Subsequent Decisions This disclosure outlines the…
Read More “[Disclosure] Celltrion (068270) – Treasury Share Acquisition Decision / 2024-10-25” »
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Following the exercise of stock options, 170,300 new common shares will be issued and additionally listed on October 29, 2024. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Why Verifying Additional Listing Completion and Share Count Update Is Necessary This…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a correction disclosure raising its FY2024 consolidated revenue forecast from KRW 4.1564T to KRW 4.3411T, driven by successful ramp-up of Plant 4 utilization and favorable foreign exchange conditions. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed its provisional Q3 2024 consolidated revenue of KRW 1.1871T (+14.81% YoY) and operating profit of KRW 338.6B (+6.29% YoY). Cumulative revenue for the first three quarters reached KRW 3.2909T, with cumulative operating profit at KRW 994.4B. 📊 [Key Disclosure Details & Financial…